Annual General Meeting CEO Presentation

Annual General Meeting
CEO Presentation
27 July 2018
1

IMPORTANT NOTICE
This presentation is given on behalf of BlisTechnologies Limited. Information in this presentation:
•Should be read in conjunction with BlisTechnologies’ Annual Reports, Interim Reports and
market releases on NZX;
•May contain projections or forward-looking statements about BlisTechnologies which are based
on current expectations and involve risks and uncertainties; BlisTechnologies’ actual results or
performance may differ materially from these statements;
•Is for general information purposes only, and does not constitute investment advice;
•Is current at the date of this presentation unless otherwise stated.
While all reasonable care has been taken in compiling this presentation to the maximum extent
permitted by law, BlisTechnologies and its directors, officers, employees and advisors accept no
responsibility for any errors or omissions.
2

The Leadership Team
CEO
Science &
R&D
Finance &
Operations
Marketing &
Sales
3

Summary
Attractive profitable growth with current mix of ingredient and finished
product sales.
Step Change growth with partners who can bring scale and capability to:
+Consumer reach
+Untapped therapeutic pathways
+Food / Pet initiatives
Deliberate investment in the future:
+Branding and Marketing / Education
+Evidence base, Regulatory approvals
+Supply Chain
+Post patent planning
4

Strategic
Priorities
5

Strategic priorities
6
Positioning
+Consistency of value proposition and development of the BLIS brand.
Building new market opportunities for BLIS branded finished products.
Supplychain
+Ongoing focus ensuring the right quality and capacity throughout the
supply chain to support growth initiatives.
Pipeline
+R & D activity to support growth long term capitalizing on existing IP
and generating new IP.
Addressable markets:
+Oral (Dental, Halitosis)
+Ear, Nose and Throat
+Skin

Performance
Review
7

$0
$1,000,000
$2,000,000
$3,000,000
$4,000,000
$5,000,000
$6,000,000
$7,000,000
$8,000,000
FY14FY15FY16FY17FY18Guidance
FY19
Annual Revenue
Financial Performance
+Steady annual growth (FY18 one off impact)
+Quarterly revenue recovery
+Cost management, to deliver profitable growth
+Ongoing investment in marketing and pipeline
-$1,500,000
-$1,000,000
-$500,000
$0
$500,000
$1,000,000
$1,500,000
$2,000,000
Q1 FY18Q2 FY18Q3 FY18Q4 FY18Q1 FY19
Quarterly performance
RevenueEBITDA
8
+

Non financial performance
+Market expansion activity
+Upgrade of finished product
portfolio in preparation for
similar launches overseas
+Change in distributor
relationship for the New Zealand
Pharmacy market including
expanded promotion to medical
health professionals.
+Approval by the Australia
Therapeutic Goods
Administration for BLIS K12® as
a complementary medicine.
+Callaghan growth grant –20%
rebate on qualifying R & D
Regulatory approvals pendingBLIS strain
AustraliaM18
CanadaM18
IndiaK12, M18
IranK12, M18
RussiaK12
South KoreaK12
TurkeyExpanded access
USA (no objection GRAS)M18
9

Growing the
Business
10

Focus on Finished Products
FP portfolio set for new market
opportunities
NZ pharmacy performance
+YTD highest selling throat lozenge
Online activity including recent
Amazon USA launch
Europe Model –Co Branded,
consistent value proposition
Mar-17
Apr-17
May-17
Jun-17
Jul-17
Aug-17
Sep-17
Oct-17
Nov-17
Dec-17
Jan-18
Feb-18
Mar-18
Apr-18
May-18
Jun-18
Sales NZ$
NZ Sales to wholesalers
Previous NZ distributor Radiant
11

BLIS Portfolio –set for new
market initiatives
Prevention of ENT infections, and boosting immunity
Oral Care
12

New Partnerships for growth
+Radiant Health –NZ
+Bluestone Pharma Europe/ Middle East expansion (7 new
partnerships)
+Raj NakraAssociates -India
+Ju Yeong NS Co -South Korea
+Good progress in establishing a relationship to expand
our Australia business
13

Pipeline Focus
New strain development
+Skin probiotic under development
+Prioritisation and development of other strains from our
library
Novel product formats
Ongoing clinical trials providing expanded evidence
Market access/ Regulatory expansion
Growing IP portfolio (patents, trade marks, trade
secrets)
14

Outlook
15

Growth drivers remain strong
Strong differentiation and brand recognition
New market expansion
Robust pipeline
Outlook
16

Guidance
Current Guidance
+Guidance for the full financial year ending 31 March 2019
is for revenue in excess of $7.0 m, an EBITDA in excess of
$0.6 m and a small profit emphasising the steady business
growth we have experienced over the last four years.
17

Questions
18

Thank you
19